Clinical trial

Jigsaw puzzle of the brain
#Alzheimer's #Antibody #Clinical trial #Cognitive impairment #Drug development #Drug discovery #Phase III trial

New Alzheimer’s treatment reduces decline in Phase III trial

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain.  Eisai and Biogen’s anti-amyloid beta (Aβ) protofibril antibody lecanemab met the primary endpoint and… Read More

#News

Covid patient receiving oxygen
#Antivirals #Clinical trial #Covid-19 #Human trials

POC study proves efficacy of zapnometinib in severe Covid-19

A proof of concept (POC) study has shown the clinical benefit of zapnometinib in patients with severe Covid-19 and supports further evaluation in severe viral diseases. Atriva Therapeutics and investigators will continue to evaluate the RESPIRE data and will provide an update on the full dataset in due course. The POC… Read More

#Covid-19 #News #Trending News

Colorectal cancer
#Clinical trial #Immunotherapy #Oncology

Excitement at rectal cancer immunotherapy breakthrough

Listen to this article on the DDW Podcast: A ground breaking ‘immunoablative’ neoadjuvant immunotherapy clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has reported a 100% complete response rate in MMRd locally advanced rectal cancer. Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New… Read More

#Exclusive Content

#Clinical trial #Immunology / Virology & Vaccines #Rabies

Promising first clinical trial data for new rabies vaccine candidate

Researchers from the University of Oxford have today reported new findings from a Phase I clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG. The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has… Read More

#News

#Clinical trial #Investment

uMotif raises $25.5m to expand clinical trial software  

uMotif today announced a new investment of $25.5 million from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif’s unique patient-first software platform for clinical research.  The company’s software is designed to provide… Read More

#News

#Boehringer Ingelheim #Clinical trial #Idiopathic pulmonary fibrosis

Boehringer Ingelheim reports positive data for lung therapy  

Boehringer Ingelheim’s investigational therapy for idiopathic pulmonary fibrosis (IPF) has shown positive data in a Phase II clinical trial, the company has announced.   The company is investigating its oral phosphodiesterase 4B (PDE4B) inhibitor (BI 1015550) as a potential treatment for people with IPF.   In a… Read More

#News

Mosquito
#Clinical trial #Immunology / Virology & Vaccines #NIAID

Early positive results for mosquito-borne virus vaccine  

A vaccine for a range of mosquito-borne viruses has received positive results from a Phase I clinical trial.  Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) have developed a vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus… Read More

#News

#Business #Clinical trial

Boyds expands clinical operations team

Drug development consultancy Boyds has bolstered its clinical trials expertise with the appointment of Caroline Corbett as Director of Clinical Operations.   As Director of Clinical Operations at Boyds, Corbett will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth… Read More

#News

#Biopharma #Clinical trial #Covid-19 #Genetics #Vaccines

This week in drug discovery (18-22 April)  

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new… Read More

#News

#Clinical trial #Drug development #Drug discovery #Therapeutics

Rani Therapeutics initiates Phase I study osteoporosis drug 

Rani Therapeutics, a clinical stage biotherapeutics company focused on the oral delivery of biologics, has initiated a Phase I study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via capsule.  The first subject has been administered RT-102… Read More

#News

#Biotherapeutics #Clinical trial #Covid-19 #FDA

UK becomes first country to approve a Covid-19 antiviral pill 

The MHRA has authorised Merck and Ridgeback Biotherapeutics’ molnupiravir pill for the treatment of at-risk Covid-19 patients, following positive clinical trial results. Molnupiravir is the first oral antiviral medicine authorised for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk… Read More

#News

#Clinical trial #Covid-19 #Moderna

Positive data from Moderna study of Covid-19 vaccine in children 

Moderna has announced positive interim data from its Phase II/III study (KidCOVE) of mRNA-1273, the company’s vaccine candidate against Covid-19, in children six to 12 years of age.   This interim analysis showed a robust neutralising antibody response after two doses of mRNA-1273 at the 50µg dose level with a favourable… Read More

#News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Research

Moderna: new clinical data on its Covid-19 vaccine 

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared… Read More

#Covid-19 #News #Trending News

#Biotechnology #Clinical trial #Data #Psychedelics

First patient receives low-dose psilocybin for rare headache disorder 

Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA).   The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being… Read More

#News

#Clinical trial #Drug development #Drug discovery #Drug targets

Data shows promise for patients with asthma and comorbid nasal polyps 

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1   Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an… Read More

#News

#Biotherapeutics #Clinical trial #mRNA #Therapeutics

Positive interim results from Phase I study for sickle cell disease treatment

Massachusetts-headquartered Fulcrum Therapeutics has announced positive interim results from the ongoing single and multiple-ascending dose (SAD and MAD) Phase I trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent and selective small molecule inhibitor of EED designed to increase the expression of fetal hemoglobin (HbF) with the… Read More

#News #Trending News